PharmaTimes reports Gryphon Investors has announced an agreement with two
Gryphon has invested funds in Synteract, which is a CRO with expertise in oncology and central nervous system drugs, and Vince Associates, which is a leading provider of services that specialize in sleep disorders research. Nick Orum, head of Gryphon’s Business Services Group mentions that the agreement has been a “year-long effort … to become an active participant in the dynamic, growing field of outsourced drug development services”.
No comments:
Post a Comment